Tumour-associated angiogenesis in human colorectal cancer

Colorectal Disease

Volumn 9, Issue 1, 2007, Pages 3-14

  Rmali, K A ^a   Puntis, M C A ^a   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Angiogenesis; Colorectal cancer; Tumour endothelial markers; Vascular endothelial growth factors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTHRAX TOXIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIGEN; MESSENGER RNA; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; TIE RECEPTOR; TUMOR ENDOTHELIAL MARKER PROTEIN 1; TUMOR ENDOTHELIAL MARKER PROTEIN 2; TUMOR ENDOTHELIAL MARKER PROTEIN 3; TUMOR ENDOTHELIAL MARKER PROTEIN 5; TUMOR ENDOTHELIAL MARKER PROTEIN 7; TUMOR ENDOTHELIAL MARKER PROTEIN 8; TUMOR ENDOTHELIAL MARKER PROTEIN 9; TUMOR MARKER; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON WILLEBRAND FACTOR;

CANCER INHIBITION; CARCINOGENESIS; COLORECTAL CANCER; DISEASE SEVERITY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

COLORECTAL NEOPLASMS; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845337061     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2006.01089.x     Document Type: Review

References (81)

1. Folkman J. Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumours. Ann Surg 1972; 175: 409-16.
3. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 5;267: 10931-4.
4. Folkman J. What is the evidence that tumours are angiogenesis and metastasis. J Natl cancer Inst 1991; 82: 4-6.
5. Klagsbrun M. Regulators of angiogenesis: Stimulators, inhibitors, and extracellular matrix. J Cell Biochem 1991; 47: 199-200.
6. Folkman J. The role of angiogenesis in tumour growth. Semin Cancer Biol 1992; 3: 65-71.
7. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW. Initial stages of tumour cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000; 19;92: 143-7.
8. Gimbrone MA Jr, Leapman S, Cotran R, Folkman J. Tumour dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261-76.
9. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
10. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-7.
11. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-9.
12. Bouck N. Tumour angiogenesis: The role of oncogenes and tumour suppressor genes. Cancer Cells 1990; 2: 179-85.
13. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumour growth and produces long-term dormancy of metastases. J Clin Invest 1998; 101: 1055-63.
14. Hanahan D, Folkman J. patterns and emerging mechanisms of the angiogenic switch during tumourigenesis. Cell 1996; 86: 353-64.
15. Ellis LM. A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am Surg 2003; 69: 3-10.
16. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 15: 851-8.
17. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
18. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Folkman J. Tumour vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-8.
19. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989; 8: 3801-6.
20. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi BZ, Cohen T, Gengrinovitch S. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999; 13: 9-22.
21. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 21;255: 989-91.
22. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-86.
23. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Bohlen P. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 72: 835-46.
24. Masuda M, Yasuhara S, Yamashita M, Shibuya M, Odaka T. Nucleotide sequence of the murine thyroid hormone receptor (alpha-1) cDNA. Nucleic Acids Res 1990; 18: 3055.
25. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991; 6: 1677-83.
26. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, de Waal R, Alitalo K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154: 1381-90.
27. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-8.
28. James L, Alane G, Jean Y, Shiuh-Ming L, Hava A, Wood WI. Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4. Cell Biol 1996; 93: 1988-92.
29. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA.Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Cell Biol 1998; 95: 548-53.
30. Jiang ZG. Angiogenesis activity of tissues and cells of different malignancies. Zhonghua Zhong Liu Za Zhi 1989; 11: 165-7.
31. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumour cell lines. Cancer Res 1986; 46: 5629-32.
32. Rosenthal RA, Megyesi JF, Henzel WJ, Ferrara N, Folkman J. Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 1990; 4: 53-59.
33. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-35.
34. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
35. Hatva E, Kaipainen A, Mentula P, Jaaskelainen J, Paetau A, Haltia M, Alitalo K. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumours. Am J Pathol 1995; 146: 368-78.
36. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
37. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
38. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumourigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
39. Hatva E, Bohling T, Jaaskelainen J, Persico MG, Haltia M, Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 1996; 148: 763-75.
40. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
41. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumour: A role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95: 10820-5.
42. Weidner N. Intratumour microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
43. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist 2000; 5 (Suppl. 1): 11-15.
44. Tokunaga T, Oshika Y, Abe Y et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998; 77: 998-1002.
45. Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, Ochiai T. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: Correlation with clinicopathological factors and tumour markers. Oncol Rep 2000; 7: 333-8.
46. Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J, Kerin MJ Jr, Monson JR. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279-85.
47. Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, Cavrini G, Mazziotti A, Grigioni WF. Relevance of biologic markers in colorectal carcinoma: A comparative study of a broad panel. Cancer 2002; 94: 647-57.
48. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada M Jr. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94: 1070-6.
49. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999; 81: 845-50.
50. Xie Z, Huang X, Li J. Liver metastasis in colorectal cancer and tumour angiogenesis. Zhonghua Wai Ke Za Zhi 1999; 37: 336-7.
51. Cascinu S, Graziano F, Catalano V et al. Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clin Exp Metastasis 2000; 18: 651-5.
52. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 2003; 200: 183-94.
53. Kawakami M, Furuhata T, Kimura Y, Yamaguchi K, Hata F, Sasaki K, Hirata K. Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J Exp Clin Cancer Res 2003; 22: 229-37.
54. Rmali KA, Puntis MCA, Jiang WG. Analysis of angiogenic factors, VEGFs, their receptor and angiogenic markers in human colon cancer. Br J Cancer 2003; 88 (Suppl. 1): S46.
55. Kazama S, Kitayama J, Watanabe T, Nagawa H. Expression pattern of vascular endothelial growth factor-C in human colorectal normal mucosa and neoplastic mucosa. Hepatogastroenterology 2004; 51: 391-5.
56. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004; 95: 32-39.
57. Kaio E, Tanaka S, Kitadai Y, Sumii M, Yoshihara M, Haruma K, Chayama K. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2003; 64: 61-73.
58. Witte D, Thomas A, Ali N, Carlson N, Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002; 22: 1463-6.
59. Cassano A, Bagala C, Battelli C, Schinzari G, Quirino M, Ratto C, Landriscina M, Barone C. Expression of vascular endothelial growth factor, mitogenactivated protein kinase and p53 in human colorectal cancer. Anticancer Res 2002; 22: 2179-84.
60. St Croix B, Rago C, Velculescu V et al. Genes expression in human tumour endothelium. Science 2000; 289: 1197-201.
61. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumour endothelial markers are conserved in mice and humans. Cancer Res 2001; 61: 6649-55.
62. Van der Vieren M, Crowe DT, Hoekstra D, Vazeux R, Hoffman PA, Grayson MH, Bochner BS, Gallatin WM, De S. The leukocyte integrin Dß2 binds VCAM-1: Evidence for a binding interface between I domain and VCAM-1. J Immunol 1999; 163: 1984-90.
63. Rmali KA, Puntis MC, Jiang WG. TEM-8 and tubule formation in endothelial cells, its potential role of its vW/TM domains. Biochem Biophys Res Commun 2005; 334: 231-8.
64. Wigelsworth DJ, Krantz BA, Christensen KA, Lacy DB, Juris SJ, Collier RJ. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J Biol Chem 2004; 279: 23349-56.
65. Lee JO, Rieu P, Arnaout MA, Liddington R. Crystal structure of the A domain from the subunit of integrin CR3 (CD11b/CD18). Cell 1995; 80: 631-8.
66. Santelli E, Bankston LA, Leppla SH, Liddington RC. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 2004; 4: 905-8.
67. Bradley KA, John A, Young JA. Anthrax toxin recepyor proteins. Biochem Pharmacol 2003; 65: 309-14.
68. Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St. Croix B. TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 2004; 64: 817-20.
69. Beauregard KE, Collier RJ, Swanson JA. Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell Microbiol 2000; 2: 251-8.
70. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci USA 2002; 99: 7045-8.
71. Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH, Van de Woude GF. Suppression of ras-mediated transformation and inhibition of tumour growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci USA 2001; 98: 4089-94.
72. Bonuccelli G, Sotgia F, Frank PG et al. Anthrax Toxin Receptor (ATR/ TEM-8) is highly expressed in epithelial cells lining the toxin's three sites of entry (lung, skin and intestine). Am J Physiol Cell Physiol 2005; 288: 1402-10.
73. Liu S, Leppla SH. Cell surface tumour endothelial marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J Biol Chem 2003; 278: 5227-334.
74. Scobie HM, Young JA. Interactions between anthrax toxin receptors and protective antigen. Curr Opin Microbiol 2005; 8: 106-12.
75. Rmali KA, Puntis MC, Jiang WG. Prognostic values of tumour endothelial markers in patients with colorectal cancer. World J Gastroenterol 2005; 11: 1283-6.
76. Rmali KA, Watkins G, Harrison G, Parr C, Puntis MCA, Jiang WG. Tumour endothelial marker 8 (Tem-8) in human colon cancer and its association with tumour progresion. Eur J Surg Oncol 2004; 30: 948-53.
77. Rmali KA, Al-Rawi MAA, Parr C, Puntis MCA, Jiang WG. Upregulation of tumour endothelial marker-8 (TEM-8) by interleukin-1 β and its impact in IL-1 β induced angiogenesis. Int J Mol Med 2004; 14: 75-80.
78. Riche F, Dosquet C, Panis Y, Valleur P, Laisne MJ, Briard C, Wautier JL. Levels of portal and systemic blood cytokines after colectomy in patients with carcinoma or Crohn's disease. J Am Coll Surg 1995; 180: 718-24.
79. Strassmann G, Jacob CO, Fong M, Bertolini DR. Mechanisms of paraneoplastic syndromes of colon-26: Involvement of interleukin 6 in hypercalcemia. Cytokine 1993; 5: 463-8.
80. Jarry A, Vallette G, Cassagnau E, Moreau A, Bou-Hanna C, Lemarre P, Letessier E, Le Neel JC, Galmiche JP, Laboisse CL. Interleukin 1 and interleukin 1beta converting enzyme (caspase 1) expression in the human colonic epithelial barrier. Caspase 1 downregulation in colon cancer. Gut 1999; 45: 246-51.
81. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. IL-1 is required for tumour invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 4;100: 2645-50.